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43.3% of patients had a dose reduction. Adverse events led to treatment modifica-
tions in 60.0% of patients. Among patients who discontinued treatment, 27.3%
discontinued within 18 weeks (9.1% in 0-6 weeks, 6.1% in 7-12 weeks, and 12.1% in
13-18 weeks). Among those who discontinued, 30.3% discontinued due to AEs.
CONCLUSIONS: Objective response rate (35.5%) was higher than that observed in
expanded access trial (17%) but lower than that observed in randomized clinical trial.
A large proportion (60%) of patients experienced treatment modifications due to AEs.
About 15.2% of treatment discontinuations occurred within the first two cycles. This
real-worldclinicalpractice studysuggests that tolerabilitywithsunitinib isachallenge
for physicians in the clinical care of mRCC patients in the UK.
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OBJECTIVES: To determine the rate of comorbid cardiovascular diseases in pa-
tients with metastatic colorectal cancer (mCRC), as comorbidities may impact
treatment decisions, prognoses, and quality of care.METHODS: From the PHARMO
Record Linkage System (RLS), including among other things, drug dispensing and
hospitalisation records of approximately 3.2 million residents in The Netherlands,
all patients with a primary or secondary hospital discharge code for CRC and dis-
tant metastasis between 2000 and 2008 were selected and defined as patients with
mCRC. The first discharge diagnosis defining metastases served as the index date.
Prevalent cardiovascular comorbidities were assessed during the 12 months prior
to the index date and patients were required to be registered in the PHARMORLS in
this period to be included in the study cohort. Cardiovascular comorbidities were
captured using information on drugs dispensed for the treatment of cardiovascular
diseases in the outpatient setting, which include antihypertensive agents, anti-
thrombotic agents, agents acting on the renin-angiotensin system, and cardiac
therapy. Results were summarised descriptively by the number and proportion of
patients receiving these agents. RESULTS:A total of 2,964 patientswithmCRCwere
included in the analysis. Mean ( standard deviation) age at diagnosiswas 68 ( 12)
years and 53% were male. Overall, cardiovascular comorbidities were observed in
50% of the patients, with 27% having diseases requiring antithrombotic treatment
(such as arterial thromboembolism, strokes, and deep vein thrombosis) and 11%
having cardiac therapy. CONCLUSIONS: Cardiovascular comorbidities are com-
monly seen in patientswithmCRC,whichmight be explained by the highmean age
at diagnosis. Consideration of these conditions should be an integral part of the
treatment strategy in individual patients with mCRC.
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OBJECTIVES: The majority of ovarian cancer cases are not diagnosed until late
stages, which carry dramatically greater risk of death. Obese women experience
higher rates of ovarian cancer, and are at higher risk of ovarian cancer mortality.
Delayed diagnosis of ovarian cancer in obesewomenmay explain this relationship.
METHODS: A MEDLINE search was performed to systematically identify articles
that present stage of diagnosis of ovarian cancer by BMI. We included 7 of 252
articles identified in the search, and conducted a meta-analysis of 3,275 cases of
ovarian cancer in these 7 studies to determine if there was an association between
stage at diagnosis and BMI. RESULTS: 74% of cases were diagnosed at a late stage;
15% had a BMI of at least 30 kg/m2. The data showed a significant downward trend
in proportion of late-stage cases by BMI. Patientswhowere underweightweremost
likely to be diagnosed at a late stage (81%). Women with higher BMIs were less
likely to be diagnosed at a late stage, with 72% of overweight women and 71% of
obese women having stage III/IV ovarian cancer (p0.009). The odds of late-stage
disease were lower in high-BMI women compared to the odds of late-stage disease
in women with a normal BMI (OR0.783; 95%CI: 0.623-0.987). CONCLUSIONS:
These findings suggest a modest inverse association between BMI and stage at
diagnosis. This is contrary to the hypothesized relationship, and could be ex-
plained by diagnostic differences, increased symptoms of ovarian cancer in the
obese, tumor characteristics, or cancer-related weight loss. Future studies should
investigatewhy obesewomen have highermortality rates despite earlier diagnosis
of ovarian cancer.
PCN5
USING HEALTH CLAIMS DATA TO STUDY PATTERNS OF CERVICAL CANCER
SCREENING AND DIAGNOSIS IN A STATE MEDICAID FEE-FOR-SERVICE
POPULATION (FUNDING: AHRQ – P20-HS15930)
Nadpara P1, Madhavan S1, Khanna R2, Atkins E1, Smith MJ3, Miller LA1
1West Virginia University, Morgantown, WV, USA, 2University of Mississippi, University, MS,
USA, 3University of Oklahoma, Tulsa, OK, USA
OBJECTIVES: Cervical cancer (CC) is the 11th most common cancer among Ameri-
can women. In West Virginia (WV), it is second most common cancer and also
second leading cause of cancer-related mortality in 25-44 years aged women. The
study objective was to use claims data for surveillance of CC and precancerous
cervical intraepithelial lesions (PCL) among women enrolled in the state Medicaid
Fee-For-Service program. METHODS: Enrollment, demographic, and claims data
for continuously enrolled female recipients aged 18-64 years for the period 2003 to
2008 were analyzed for this study. All medical claims were aggregated to reflect
each recipient’s medical utilization. RESULTS: Pap smear testing prevalence de-
clined between 2003 (238.9/1,000) and 2008 (158.8/1,000). During the study period,
approximately 58% women had at least 1 Pap smear test. While prevalence of CC
diagnosis declined from 139 to 113 during the study period, the prevalence of
cervical intraepithelial neoplasia-1 (CIN1) and CIN2 increased to 85 and 207 from
2003 to 2008, respectively. Approximately 73% of the women received Pap testing
during the 365 day period prior to their index date of CC or PCL diagnosis. Poisson
regression model found age, race, location, contraceptive use, access to provider
and co-morbidity status as significant (p.05) predictors of persistence with Pap
testing. Ordinal logistic regression model predicted Pap screening persistence as a
significant factor that was associated with the likelihood of an initial diagnosis of
CC, high grade PCL, or low grade PCL. Only 10% of the women received appropriate
follow-up care following a diagnosis of low grade PCL; for high grade PCL diagnosis
32% of the women received appropriate follow-up care. CONCLUSIONS: The study
found declining screening rates for CC during the study period in fee-for-service
Medicaid population. Disparities in appropriate follow-up care following a diagno-
sis of high grade or low grade PCL were also identified.
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OBJECTIVES: Age-adjusted all-site cancer incidence and overall cancer mortality
rates are higher in West Virginia (WV) compared to the US. Population-based
screening is an effective tool that helps in early detection\treatment of cancer.
However, incidence of late-stage diagnosis remains frequent among screening-
amenable cancers in WV. The objective of this study is to identify: (1) breast, pros-
tate and colorectal cancer screening-behavior and (2) factors associated with late-
stage breast, prostate and colorectal cancer diagnosis among elderly West
Virginians.METHODS: Cancer stage and demographic information for individuals
with incidence of breast, prostate or colorectal cancer during years 2002-2005 were
extracted from theWVCancer Registry (WVCR) database. Data on cancer screening
behavior were obtained from Behavioral Risk Factor Surveillance System (BRFSS)
survey for 2002-2005. RESULTS: Age-adjusted late-stage colorectal cancer inci-
dence rates were significantly higher inWV compared to the US population during
2002-2005. Invasive incidence rates (per 100,000) were higher among both men
(WV: 67.0; US: 56.4) and women (WV: 44.2; US: 41.9). Nearly half of all colorectal
cancers were diagnosed at regional or distant stage. WV rates for late-stage breast
and prostate cancer incidence were lower compared to US. Screening rates for all 3
cancers in WV were lower compared to US; Colorectal Cancer (46.3% vs. 53.8%),
Breast Cancer (72.5% vs. 74.6%), Prostate Cancer (59.7% vs. 61.6%). CONCLUSIONS:
Unlike CDC report [MMWR-2010;59(No.SS-9)], West Virginians in this study had
lower incidence of late-stage Breast and Prostate Cancer compared to US. However,
colorectal cancer late- stage incidence rates remained higher inWVvs. theUS. This
difference in late-stage cancer incidence rates might be explained partially by dif-
ferences in screening use, which also remained lower for all three cancers in WV
compared to US. Patient, provider and health care system related factors may
account for variation in the proportion of populations that get screened.
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OBJECTIVES: A biological and genetical variation of lung cancer is non-small cell
lung cancer (NSCLC) bearing activatingmutations in the tyrosine kinase domain of
the epidermal growth factor receptor (EGFR m). In this population the EGFR ty-
rosine kinase inhibitors (TKIs) erlotinib and gefitinib have shown significant in-
crease in progression-free survival (PFS) compared to chemotherapy. Erlotinib is
not yet licensed for this indication; however, an EMA marketing authorization
submission is currently ongoing. Therefore both therapies will be competing to be
primary choice in treatment naïve patients with EGFR m NSCLC; hence, in the
absence of direct head-to-head comparison, there is a need for indirect treatment
comparison (ITC) assessment. METHODS: Published phase-III evidence was used
as the basis for the ITC. The Bucher et al. ITC methodology was applied to the PFS
hazard ratios (HRs) obtained by comparing the TKIs versus chemotherapy. Erlotinib
obtained a HR of 0.16 (95%CI: 0.10-0.26, p0.0001) based on the OPTIMAL trial;
gefitinib obtained the following PFS HRs vs. chemotherapy: IPASS trial: 0.48 (95%CI:
0.36-0.64, p0.001); WJTOG trial: 0.33 (95%CI: 0.20-0.54, p0.0001) and NEJGSG trial:
0.30 (95%CI: 0.22-0.41, p0.001). Besides comparing the erlotinib PFS HR with each
single gefitinib trial, erlotinib was compared to the pooled gefitinib evidence.
RESULTS: Comparing the PFS HRs of erlotinib versus gefitinib based on the OPTIMAL
trial and the IPASS trial resulted in a statistically significant PFS difference (ITC HR:
0.33; 95%CI: 0.19-0.58; p0.0001). This statistically significant PFS difference was
also observed when comparing OPTIMAL versus WJTOG (ITC HR: 0.48; 95%CI: 0.24-
0.97, p0.0395) and versus NEJGSG (ITC HR: 0.53; 95%CI: 0.30-0.9, p0.0307). Com-
paring erlotinib vs. the pooled gefitinib phase-III evidence confirmed these
findings. CONCLUSIONS: According to the underlying indirect comparison of pub-
lished phase-III evidence, erlotinib is the most efficacious EGFR TKI in first-line
EGFR m NSCLC.
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